MRP (Multidrug Resistance-Associated Protein) are a family of membrane transporters involved in drug efflux and cellular detoxification. These proteins play a significant role in cancer by contributing to multidrug resistance (MDR), a major obstacle in chemotherapy. Several important MRPs have been identified: 1) MRP1 (ABCC1). MRP1 is primarily localized in the plasma membrane and functions as an ATP-dependent efflux pump for a wide range of drugs, including chemotherapeutic agents. Overexpression of MRP1 in cancer cells leads to decreased drug accumulation and reduced drug efficacy, leading to resistance to chemotherapy; 2) MRP2 (ABCC2). MRP2 is mainly expressed in the liver, intestine, and kidney. In cancer, MRP2 is also associated with resistance to a variety of anticancer drugs. Its expression is often elevated in tumour tissues, contributing to drug efflux and limiting drug accumulation within cancer cells; 3) MRP3 (ABCC3). MRP3 is expressed in various tissues, including the liver, intestine, and kidney. It transports a broad range of organic anions and anticancer drugs. Increased MRP3 expression has been associated with chemoresistance in hepatocellular carcinoma and colorectal cancer; 4) MRP4 (ABCC4). MRP4 is widely expressed in normal tissues and various cancer types and transports a variety of endogenous compounds and drugs, including nucleoside analogues and anticancer agents. Overexpression of MRP4 has been linked to resistance to nucleoside analogues and certain chemotherapeutic drugs; 5) MRP5 (ABCC5). MRP5 is involved in the transport of nucleotides, nucleoside analogues, and cyclic nucleotides; 6) MRP6 (ABCC6). MRP6 is primarily expressed in the liver and kidneys. The role of MRP6 in cancer is less well-studied compared to other MRPs. MRPs are often upregulated in cancer cells in response to chemotherapy, leading to decreased drug efficacy and MDR. Their overexpression and increased activity result in the efflux of anticancer drugs, reducing their intracellular concentration and preventing them from exerting their cytotoxic effects. Consequently, MRP inhibitors are being explored as potential therapeutic agents to overcome multidrug resistance and improve the effectiveness of chemotherapy in cancer treatment. We provide a large product catalogue of research reagents for studying MRP related proteins, including MRP1 antibodies, MRP2 antibodies, MRP8 antibodies, and MRP3 antibodies. Explore our full MRP related proteins product range below and discover more, for less.